Coherent, Zeiss Supplying Lasers Free For Visudyne Treatment IND Study
This article was originally published in The Gray Sheet
Executive Summary
Laser manufacturers Coherent and Zeiss are providing their device at no charge to physicians participating in Ciba Vision's treatment IND program for the photodynamic age-related macular degeneration treatment Visudyne (verteprofin).
You may also be interested in...
Coherent, Zeiss Eye PDT Market Opportunity Pending Visudyne NDA Approval
Coherent, Inc. and Zeiss Humphrey Systems are preparing to compete head-to-head for the placement of photodynamic therapy (PDT) lasers to perform "wet" age-related macular degeneration (AMD) therapy in conjunction with QLT PhotoTherapeutics' Visudyne (verteporfin for injection) pending imminent FDA approval for the combined drug/device treatment.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.